<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04719572</url>
  </required_header>
  <id_info>
    <org_study_id>antiosteoporosis301</org_study_id>
    <nct_id>NCT04719572</nct_id>
  </id_info>
  <brief_title>Intervention Study of Drugs in Patients Osteopenia and Osteoporosis</brief_title>
  <official_title>Intervention Study of Different Anti-osteoporpsis Intervention Strategies in Patients With Osteopenia and Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Jishuitan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Aerospace General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 12 months, randomized, multicenter, open-label, parallel-group study in&#xD;
      postmenopausal women and male aged 50 years or old with osteoporosis or osteopenia in China&#xD;
      to evaluate the efficacy and safety of different anti-osteoporpsis intervention strategies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 12 months,randomized, multicenter, open-label, pragmatic-group study in&#xD;
      postmenopausal women and male aged 50 years or old with osteoporosis or osteopenia in China&#xD;
      to evaluate the efficacy and safety of different anti-osteoporpsis intervention strategies,&#xD;
      including&#xD;
&#xD;
        -  Group1: Basic treatment group (elemental calcium 600mg/ day + vitamin D 1000IU/day)&#xD;
&#xD;
        -  Group2: Basic treatment+ anti-osteoporosis drug group (alendronate, zoledronate,&#xD;
           tripopeptide, denosumab, activated vitamin D, menatetrenone soft capsules according to&#xD;
           the patient's condition)&#xD;
&#xD;
        -  Group3: Basic treatment + non-drug treatment group(diet, exercise, rehabilitation&#xD;
           therapy).&#xD;
&#xD;
      Eligibility for participation will be determined by medical history, physical examination,&#xD;
      and laboratory results obtained during a screening visit. About 180 postmenopausal women and&#xD;
      elderly male with osteoporosis or osteopenia will be included in this study.&#xD;
&#xD;
      All subjects will be given informed consent before starting any examination and test. The&#xD;
      following data of all subject will be collected: liver and kidney function, HbA1c, fasting&#xD;
      blood glucose, fasting lipid profile, serum calcium, serum phosphate, parathyroid hormone,&#xD;
      25-hydroxy vitamin D, bone turnover markers(BTMs) (inculding serum procollagen type I&#xD;
      N-propeptide, serum C-terminal telopeptide of type I collagen,osteocalcin and alkaline&#xD;
      phosphatase), thoracic and lumbar spine X-ray, bone mineral density(BMD) by dual energy&#xD;
      X-ray.&#xD;
&#xD;
      Then they will be randomized into three groups at a 1:1 ratio. Every group will be given&#xD;
      calcium carbonate and vitamin D. In the group 2, the medication will be decided by the doctor&#xD;
      according to the patients' condition. Particularly, denosumab has not been approved for male&#xD;
      adaptation, we will sign an additional informed consent.&#xD;
&#xD;
      All subjects will be followed by visiting clinic every three months and complete the&#xD;
      examinations to assess the safety and efficacy. Safety indexes: liver and kidney function,&#xD;
      urine routine test and 24-h urine calcium. Efficacy indexes: BMD change, BTMs changes and&#xD;
      fracture reduction. All subjects will be followed 12 months and data will be collected and&#xD;
      analyzed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The efficacy on BTMs level</measure>
    <time_frame>3 months、6months、9months、12months</time_frame>
    <description>The change of BTMs level after different interventions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The efficacy on BDM level</measure>
    <time_frame>12 months</time_frame>
    <description>The change of BDM level after different interventions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fracture rate</measure>
    <time_frame>12 months</time_frame>
    <description>Fracture rate during follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The type and rate of drug adverse reactions</measure>
    <time_frame>12 months</time_frame>
    <description>The type and rate of drug adverse reactions during follow up</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Osteopenia, Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Basic treatment group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>elemental calcium 600mg/ day + vitamin D 1000IU/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Basic treatment+ anti-osteoporosis drug group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>alendronate(70mg/week), zoledronate(5mg 1/ year), tripopeptide(20ug 1/day), denosumab(120mg/month), activated vitamin D(0.25ug 1/day), menatetrenone(15mg tid) according to the patient's condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Basic treatment + non-drug treatment group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>diet, exercise, rehabilitation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Basic treatment group</intervention_name>
    <description>A total of 60 subjects were recruited in the group.</description>
    <arm_group_label>Basic treatment + non-drug treatment group</arm_group_label>
    <arm_group_label>Basic treatment+ anti-osteoporosis drug group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Basic treatment+ anti-osteoporosis drug group</intervention_name>
    <description>A total of 60 subjects were recruited in the group.</description>
    <arm_group_label>Basic treatment + non-drug treatment group</arm_group_label>
    <arm_group_label>Basic treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Basic treatment + non-drug treatment group</intervention_name>
    <description>A total of 60 subjects were recruited in the group.</description>
    <arm_group_label>Basic treatment group</arm_group_label>
    <arm_group_label>Basic treatment+ anti-osteoporosis drug group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent obtained before any trial-related activities&#xD;
&#xD;
          -  Postmenopausal women and male aged 50 years or old&#xD;
&#xD;
          -  Osteoporosis by DXA or fragility fracture history&#xD;
&#xD;
          -  Osteopenia with more than one osteoporotic risk factors&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secondary osteoporosis&#xD;
&#xD;
          -  Renal insufficiency (Ccr&lt; 35ml/min)&#xD;
&#xD;
          -  New fractures &lt; 3 months, prior bilateral hip fractures or surgical replacement.&#xD;
&#xD;
          -  Other medication contraindications&#xD;
&#xD;
          -  Malignant tumors&#xD;
&#xD;
          -  Mobility-impaired individuals&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunlin Li, M.D&amp;Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chunlin Li, M.D&amp;Ph.D</last_name>
    <phone>+86-13810921655</phone>
    <email>lichunlin301@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 15, 2021</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Chunlin Li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Anti-osteoporosis therapy</keyword>
  <keyword>men</keyword>
  <keyword>Postmenopausal women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

